-
公开(公告)号：US08398975B2
公开(公告)日：2013-03-19
申请号：US12782335
申请日：2010-05-18
申请人： Julie Rinkenberger , Ian Foltz , Avril Alfred , Simon Thomas Barry , Vahe Bedian
发明人： Julie Rinkenberger , Ian Foltz , Avril Alfred , Simon Thomas Barry , Vahe Bedian
IPC分类号： A61K39/395 , C07K16/00 , C07K16/46 , C07K16/28
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
摘要： Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
摘要翻译： 描述了靶向结合剂，针对抗原αV和bgr的这种抗体以及这些药剂的用途。 特别地，公开了针对抗原αV和bgr的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US20100330103A1
公开(公告)日：2010-12-30
申请号：US12782335
申请日：2010-05-18
申请人： Julie RINKENBERGER , Ian FOLTZ , Avril ALFRED , Simon Thomas BARRY , Vahe BEDIAN
发明人： Julie RINKENBERGER , Ian FOLTZ , Avril ALFRED , Simon Thomas BARRY , Vahe BEDIAN
IPC分类号： A61K39/395 , C07K16/28 , A61P35/00 , A61P29/00
CPC分类号： C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
摘要： Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
摘要翻译： 描述了靶向结合剂，针对抗原αV和bgr的这种抗体以及这些药剂的用途。 特别地，公开了针对抗原αV和bgr的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US20120107324A1
公开(公告)日：2012-05-03
申请号：US13141608
申请日：2009-12-21
申请人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
发明人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
IPC分类号： A61K39/395 , C07K14/435 , C07K16/00 , A61P35/00 , C12N15/62 , C12N5/10 , C12P21/08 , C07K5/08 , C07H21/04
CPC分类号： B01F5/0619 , B01F5/0613 , B01F5/0617 , B01F15/00935 , B01F2005/0639
摘要： The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
摘要翻译： 本发明涉及针对α5和bgr的靶向结合剂及其用途。 更具体地，本发明涉及针对α5和bgr的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5和bgr1的活性和/或过度产生相关的疾病和作为诊断。
-
公开(公告)号：US08119130B2
公开(公告)日：2012-02-21
申请号：US12669724
申请日：2008-07-23
IPC分类号： A61K39/395 , A61K39/00 , C12P21/08 , C07K16/00 , C07K16/28
CPC分类号： C07K16/2863 , A61K38/16 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
摘要翻译： 本发明涉及针对KDR的靶向结合剂及其用途。 更具体地，本发明涉及针对KDR的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与KDR的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号：US20100196398A1
公开(公告)日：2010-08-05
申请号：US12562533
申请日：2009-09-18
IPC分类号： A61K39/395 , C07K16/18 , C07H21/00 , A61P35/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K2317/565 , C07K2317/73 , C07K2317/92
摘要： The invention relates to targeted binding agents against CD105 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to CD105. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of CD105 and as diagnostics.
摘要翻译： 本发明涉及针对CD105的靶向结合剂及其用途。 更具体地，本发明涉及针对CD105的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与CD105的活性和/或过度产生相关的疾病和作为诊断。
-
公开(公告)号：US20120114667A1
公开(公告)日：2012-05-10
申请号：US13141564
申请日：2009-12-21
申请人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
发明人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
IPC分类号： A61K39/395 , C07K16/18 , C07H21/04 , C12N15/63 , C12N5/16 , C12P21/06 , A61P35/00 , C07K14/00 , A61K38/00 , A61P29/00 , A61P9/10 , A61P9/00 , A61P5/00 , C12N5/10 , C07K16/00
CPC分类号： C07K16/2842 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
摘要翻译： 本发明涉及针对α5和bgr的靶向结合剂及其用途。 更具体地，本发明涉及针对α5和bgr的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5和bgr1的活性和/或过度产生相关的疾病和作为诊断。
-
公开(公告)号：US20100260765A1
公开(公告)日：2010-10-14
申请号：US12669724
申请日：2008-07-23
CPC分类号： C07K16/2863 , A61K38/16 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
摘要翻译： 本发明涉及针对KDR的靶向结合剂及其用途。 更具体地，本发明涉及针对KDR的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与KDR的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号：US20090137601A1
公开(公告)日：2009-05-28
申请号：US12094367
申请日：2006-11-22
IPC分类号： A61K31/502 , C07D211/96 , A61K31/445 , A61K31/351 , A61P35/00 , A61P9/10 , A61P31/00 , C07D309/06 , C07D401/06
CPC分类号： C07D309/20 , C07C309/65 , C07D211/34 , C07D211/70 , C07D309/04 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06 , C07D409/12 , C07D413/06 , C07D417/06
摘要： The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.
摘要翻译： 本发明涉及抑制a5b1功能的化合物，其制备方法，含有它们作为活性成分的药物组合物，其作为药物的用途及其在制备用于治疗温血动物的药物中的用途，例如 作为具有显着血管生成或血管成分的疾病的人，例如用于治疗实体瘤。 本发明还涉及抑制αb1的化合物，并且还表现出对其他整联蛋白的适当选择性分布。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.023 秒)
